Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On Thursday 27th September, in Blood Cancer Awareness Month, Deutsche Bank employees across the UK will be invited to donate a day’s salary to its two UK Charities of the Year through the bank’s ‘One Day’ initiative.

For Cure Leukaemia, the funds raised will help finance a pioneering Therapy Acceleration Laboratory at the MRC Weatherall Institute of Molecular Medicine at the University of Oxford (MRC WIMM). The laboratory will  focus on developing new approaches to treat human disease, including blood cancers

This new facility, led by Professor Paresh Vyas at the MRC WIMM, will apply the very latest scientific and computational analysis to blood cancer samples collected from patients treated through the national clinical trials network led by the Centre for Clinical Haematology at Birmingham’s Queen Elizabeth Hospital.

Characterisation of the genetic characteristics of large cohorts of blood cancer patients treated with new drug and transplant therapies will make it possible to identify blood cancer patients who will respond to a specific therapy. Integration of scientific and clinical data at such an unprecedented and globally significant scale will deconvolute the complexity of cancer therapy response permitting the delivery of truly personalised medicine to patients.

Paresh VyasSpeaking about the aims of the project Professor Vyas, Director of the Oxford Centre for Haematology, said: “If we think of blood cancer like a car crash we currently treat patients after the crash has occurred. Road and car safety focusses on the prevention of these accidents and that is what we now need to do with blood cancer, prevent the crash from happening.”

“Using detailed genetic analysis, we are now in a position to understand what causes blood cancer in patients. This Therapy Acceleration Laboratory will analyse samples from a large population of patients to identify those who will benefit from specific therapies. Importantly, this will also ensure those who will not benefit are directed to treatments that will work for them, effectively personalising treatment for the disease. In ten years, the treatment of blood cancer could be unrecognisable to today.”

 

 

Similar stories

Mechanism behind repair of cancer-inducing mutations discovered

New Nature paper uncovers the precise mechanism behind how the BRCA1 protein detects and engages with DNA breaks in the genome, helping to prevent the development of breast and ovarian cancers.

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

New clinical trial for patients affected by blood cancer

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Immune cells imperfect at distinguishing friend from foe

When it comes to distinguishing a healthy cell from an infected one that needs to be destroyed, the immune system’s killer T cells sometimes make mistakes. This discovery, described today in the journal eLife, upends a long-held belief among scientists that T cells were nearly perfect at discriminating friend from foe. The results may point to new ways to treat autoimmune diseases that cause the immune system to attack the body, or lead to improvements in cutting-edge cancer treatments.

Professor Graham Ogg elected Academy of Medical Sciences Fellow

Fellows are selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.